Log In
BCIQ
Print this Print this
 

CAM2038, CAM2058

Also known as: buprenorphine

  Manage Alerts
Collapse Summary General Information
Company Camurus AB
DescriptionExtended-release combination of buprenorphine and granisetron delivered using Camurus' FluidCrystal injection depot technology.
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$151.0M

$20.0M

$131.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/20/2014

$151.0M

$20.0M

$131.0M

Get a free BioCentury trial today